查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1943239

非治疗性生物分子市场－全球产业规模、份额、趋势、机会与预测：贸易药品、终端用户、地区和竞争格局，2021-2031年

Non-Therapeutic Biomolecules Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Trade Pharma, By End user (Research, Pharma, In vitro diagnostics, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球非治疗性生物分子市场预计将从 2025 年的 286.3 亿美元成长到 2031 年的 448.3 亿美元，复合年增长率为 7.76%。

此市场领域涵盖种类繁多的蛋白质、核酸和酶，主要用于体外诊断、工业生物加工和生命科学研究，但不直接用于病患治疗。该行业的成长主要受临床对高精度分子诊断日益增长的需求以及生产製造中永续「绿色化学」的日益普及所驱动，这标誌着工业生产正朝着生物基效率和先进检测能力的方向发生根本性转变。

市场概览
预测期 2027-2031
市场规模：2025年 286.3亿美元
市场规模：2031年 448.3亿美元
复合年增长率：2026-2031年 7.76%
成长最快的细分市场 酵素
最大的市场 北美洲

然而，由于监管基因改造生物製剂安全性和核准的复杂法规结构，市场扩张面临许多障碍。遵守这些严格的国际标准可能导致商业化进程显着延迟，并增加製造商的研发成本。 MedTech Europe 的报告显示，欧洲医疗技术市场规模预计到 2024 年将达到约 1,700 亿欧元，这表明依赖这些生物分子的产业规模之大。

市场驱动因素

早期疾病检测的迫切需求推动了体外诊断 (IVD) 试剂盒和试剂需求的不断增长，成为市场成长的主要催化剂。临床检查室高度依赖非治疗性生物分子，例如单株抗体和聚合酵素，来进行感染疾病和肿瘤标记的精准检测。这种持续的依赖也体现在主要製造商的财务表现中。罗氏于 2025 年 1 月发布的「2024 财年」报告预测，该公司诊断平台业务将成长 8%，凸显了全球检测所需的大量生物材料。此外，在整个生命科学领域，基因组研究和药物研发的大规模资本投资持续推动试剂消耗。赛默飞世尔科技对 2024 财年全年营收的预测为 428.8 亿美元，这表明支持这些研究活动的庞大基础设施规模。

随着各行业向生物基效率转型，酵素在工业製造过程中的应用日益广泛，也推动了市场的发展。从生质能源到家用产品，催化蛋白正逐渐被合成化学物质所取代，以降低能源消耗和环境影响。这就需要持续、大规模地供应专为在严苛加工环境中保持稳定性而设计的专用酵素。领先的生物解决方案供应商的表现显示了这项转型的商业性可行性。根据Novonesys公司于2025年2月发布的2024年度报告，该公司旗下行星健康生物解决方案部门的有机销售额按备考基准计算增长了9%。这一成长轨迹凸显了该产业对生物催化剂的日益依赖，以实现永续性目标和更环保的生产方法监管标准。

市场挑战

复杂的法规结构，包括对基因改造生物製剂的核准和安全监管，对全球非治疗性生物分子市场的扩张构成了重大障碍。该领域的製造商，特别是那些开髮用于工业生物加工的酶和用于诊断应用的试剂的製造商，面临着严格的合规要求，而这些要求在不同司法管辖区之间差异显着。这些严格的标准迫使企业投入大量资源用于法律检验和安全资料生成，阻碍了资本向产能和创新领域的配置。由此产生的漫长核准流程造成了严重的瓶颈，延缓了先进生物基解决方案的市场准入，并削弱了那些寻求将永续产品商业化以替代传统化学产品的製造商的竞争优势。

这些监管壁垒对产业的影响显着且深远，造成的差异直接阻碍了市场效率。 2024 年 EuropaBio 的报告显示，生物防治产品（利用工业生物分子的关键领域）在欧洲获得市场核准的平均时间为 7-8 年，而其他地区仅需 2-3 年。这些显着的延误不仅增加了开发商的财务风险，也阻碍了本地投资，儘管生物基工业工具的潜在需求庞大，但实际上却阻碍了该产业的发展。

市场趋势

胜肽和蛋白质在化妆品领域的应用不断扩展，正逐步将市场焦点从临床诊断和工业流程转移开来。护肤品越来越多地添加生物活性蛋白和合成胜肽，以提供以往仅限于皮肤治疗的功能性益处，模糊了化妆品和药品之间的界限。这一趋势的特点是，专门针对皮肤修復的信号肽和生长因子实现了商业化，为专业原料供应商创造了可观的收入来源。这一高附加价值细分市场的商业性影响十分显着。根据欧莱雅于2025年2月发布的2024年财务报告，其皮肤科化妆品部门实现了9.8%的年成长，销售额累计70亿欧元。这显示消费者对经科学验证、富含生物分子的护肤产品的需求正在加速成长。

同时，人工智慧在加速生物分子发现的应用正在革新非治疗性药物的开发平臺。透过利用生成模型和机器学习，研究人员可以绕过传统高通量筛检中重复的瓶颈环节，以前所未有的速度预测蛋白质结构和酵素功能。这种技术融合使得针对特定工业和消费应用进行最佳化的新型酵素的精确设计成为可能，从而显着缩短产品上市时间和降低研发成本。为了进一步反映对计算生物学的依赖，Ginkgo Bioworks 在 2024 年 11 月的 2024 财年第三季财报电话会议上宣布，其细胞工程平台新增了 25 个项目，这标誌着业界正持续向数据驱动的生物勘探转型，以解决复杂的生物工程难题。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球非治疗性生物分子市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药品（酵素、重组蛋白、质体、胜肽、寡核苷酸、单株抗体）
    • 依最终用户（研究、製药、体外诊断（IVD）、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美非治疗性生物分子市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲非治疗性生物分子市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区非治疗性生物分子市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲非治疗性生物分子市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲非治疗性生物分子市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

13. 全球非治疗性生物分子市场：SWOT 分析

第十四章 波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Merck Group.
  • Bio-Synthesis Inc.
  • Eurogentec
  • Aviva Systems Biology
  • RayBiotech
  • Biocon Limited
  • Bio-Techne Corporation
  • Danaher Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19521

The Global Non-Therapeutic Biomolecules Market is projected to expand from a valuation of USD 28.63 Billion in 2025 to USD 44.83 Billion by 2031, registering a CAGR of 7.76%. This market sector comprises a diverse array of proteins, nucleic acids, and enzymes utilized principally for in vitro diagnostics, industrial bio-processing, and life science research, rather than for direct patient therapy. The growth of this industry is fundamentally driven by the rising necessity for high-precision molecular diagnostics within clinical settings and the increasing adoption of sustainable "green chemistry" in manufacturing, representing a structural shift toward bio-based industrial efficiency and advanced testing capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 28.63 Billion
Market Size 2031USD 44.83 Billion
CAGR 2026-20317.76%
Fastest Growing SegmentEnzymes
Largest MarketNorth America

However, market expansion encounters significant obstacles regarding the complex regulatory frameworks that govern the safety and approval of genetically modified biological agents. Compliance with these rigorous international standards can lead to substantial delays in commercialization and escalated development costs for manufacturers. Highlighting the magnitude of the industries dependent on these biomolecules, MedTech Europe reported that the European medical technology market was estimated to be approximately €170 billion in 2024.

Market Driver

The rising demand for In Vitro Diagnostic (IVD) kits and reagents acts as a primary catalyst for market growth, driven by the critical need for early disease detection. Clinical laboratories rely heavily on non-therapeutic biomolecules, such as monoclonal antibodies and polymerase enzymes, to execute sensitive assays for infectious diseases and oncological markers. This enduring reliance is reflected in the financial performance of major manufacturers; according to Roche's 'Full Year 2024 Results' released in January 2025, the company's diagnostics base business grew by 8 percent, underscoring the substantial volume of biological materials required for global testing. Additionally, the broader life sciences sector continues to fuel reagent consumption through massive capital allocation toward genomic research and drug discovery, with Thermo Fisher Scientific reporting full-year 2024 revenue of $42.88 billion in 2025, demonstrating the immense scale of the infrastructure supporting these research activities.

The expanding application of enzymes in industrial manufacturing processes concurrently propels the market as industries transition toward bio-based efficiency. Sectors ranging from bioenergy to household care are substituting synthetic chemicals with catalytic proteins to lower energy consumption and reduce environmental impact, necessitating a consistent industrial-scale supply of specialized enzymes engineered for stability in harsh processing environments. The commercial viability of this transition is evident in the performance of leading biosolution providers; according to Novonesis' 'Annual Report 2024' published in February 2025, the company's Planetary Health Biosolutions segment achieved pro forma organic sales growth of 9 percent. This trajectory highlights the rising industrial dependency on biological catalysts to meet sustainability targets and regulatory standards for greener production methods.

Market Challenge

The intricate regulatory frameworks governing the approval and safety of genetically modified biological agents constitute a substantial impediment to the expansion of the Global Non-Therapeutic Biomolecules Market. Manufacturers in this sector, particularly those developing enzymes for industrial bioprocessing and reagents for diagnostic applications, face increasingly rigorous compliance requirements that vary significantly across jurisdictions. These stringent standards force companies to allocate extensive resources toward legal validation and safety data generation, diverting capital away from production capacity and innovation. Consequently, the prolonged approval timelines create severe bottlenecks, delaying the entry of advanced bio-based solutions into the market and eroding the competitive advantage of manufacturers attempting to commercialize sustainable alternatives to traditional chemical products.

The impact of these regulatory hurdles is quantifiable and severe within the industry, creating a disparity that directly hampers market efficiency. According to EuropaBio in 2024, the average time required to obtain market authorization for biocontrol products-a key segment utilizing industrial biomolecules-was between seven and eight years in Europe, compared to just two to three years in other global regions. This extensive delay not only increases financial risk for developers but also disincentivizes regional investment, effectively stalling the sector's momentum despite the underlying demand for bio-based industrial tools.

Market Trends

The expansion of peptide and protein applications in cosmeceuticals is steadily shifting market focus beyond clinical diagnostics and industrial processing. Personal care formulations are increasingly incorporating bioactive proteins and synthetic peptides to deliver functional benefits previously reserved for dermatological therapies, effectively blurring the line between cosmetics and pharmaceuticals. This trend is characterized by the commercialization of signal peptides and growth factors tailored for skin repair, driving substantial revenue streams for specialized ingredient suppliers. The commercial impact of this high-value segment is robust; according to L'Oreal's '2024 Annual Results' in February 2025, the company's Dermatological Beauty Division achieved like-for-like growth of 9.8 percent, generating sales of €7 billion, which highlights the accelerating consumer appetite for scientifically validated, biomolecule-enriched skincare products.

Simultaneously, the integration of Artificial Intelligence for accelerated biomolecule discovery is revolutionizing the development pipeline for non-therapeutic agents. By leveraging generative models and machine learning, researchers can now predict protein structures and enzymatic functions with unprecedented speed, bypassing the iterative bottlenecks of traditional high-throughput screening. This technological convergence allows for the precise engineering of novel enzymes optimized for specific industrial or consumer applications, significantly reducing time-to-market and development costs. Validating this increasing reliance on computational biology, Ginkgo Bioworks reported in its 'Q3 2024 Financial Results' in November 2024 that the company added 25 new programs to its Cell Engineering platform, signaling a persistent industry shift toward data-driven bioprospecting to solve complex biological engineering challenges.

Key Market Players

  • Merck Group.
  • Bio-Synthesis Inc.
  • Eurogentec
  • Aviva Systems Biology
  • RayBiotech
  • Biocon Limited
  • Bio-Techne Corporation
  • Danaher Corporation

Report Scope

In this report, the Global Non-Therapeutic Biomolecules Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Therapeutic Biomolecules Market, By Trade Pharma

  • Enzymes
  • Recombinant Proteins
  • Plasmids
  • Peptides
  • Oligonucleotides
  • Monoclonal Antibodies

Non-Therapeutic Biomolecules Market, By End user

  • Research
  • Pharma
  • In vitro diagnostics(IVD)
  • Others

Non-Therapeutic Biomolecules Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Therapeutic Biomolecules Market.

Available Customizations:

Global Non-Therapeutic Biomolecules Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Therapeutic Biomolecules Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Trade Pharma (Enzymes, Recombinant Proteins, Plasmids, Peptides, Oligonucleotides, Monoclonal Antibodies)
    • 5.2.2. By End user (Research, Pharma, In vitro diagnostics(IVD), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Non-Therapeutic Biomolecules Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Trade Pharma
    • 6.2.2. By End user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Therapeutic Biomolecules Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Trade Pharma
        • 6.3.1.2.2. By End user
    • 6.3.2. Canada Non-Therapeutic Biomolecules Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Trade Pharma
        • 6.3.2.2.2. By End user
    • 6.3.3. Mexico Non-Therapeutic Biomolecules Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Trade Pharma
        • 6.3.3.2.2. By End user

7. Europe Non-Therapeutic Biomolecules Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Trade Pharma
    • 7.2.2. By End user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Therapeutic Biomolecules Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Trade Pharma
        • 7.3.1.2.2. By End user
    • 7.3.2. France Non-Therapeutic Biomolecules Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Trade Pharma
        • 7.3.2.2.2. By End user
    • 7.3.3. United Kingdom Non-Therapeutic Biomolecules Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Trade Pharma
        • 7.3.3.2.2. By End user
    • 7.3.4. Italy Non-Therapeutic Biomolecules Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Trade Pharma
        • 7.3.4.2.2. By End user
    • 7.3.5. Spain Non-Therapeutic Biomolecules Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Trade Pharma
        • 7.3.5.2.2. By End user

8. Asia Pacific Non-Therapeutic Biomolecules Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Trade Pharma
    • 8.2.2. By End user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Therapeutic Biomolecules Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Trade Pharma
        • 8.3.1.2.2. By End user
    • 8.3.2. India Non-Therapeutic Biomolecules Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Trade Pharma
        • 8.3.2.2.2. By End user
    • 8.3.3. Japan Non-Therapeutic Biomolecules Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Trade Pharma
        • 8.3.3.2.2. By End user
    • 8.3.4. South Korea Non-Therapeutic Biomolecules Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Trade Pharma
        • 8.3.4.2.2. By End user
    • 8.3.5. Australia Non-Therapeutic Biomolecules Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Trade Pharma
        • 8.3.5.2.2. By End user

9. Middle East & Africa Non-Therapeutic Biomolecules Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Trade Pharma
    • 9.2.2. By End user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Therapeutic Biomolecules Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Trade Pharma
        • 9.3.1.2.2. By End user
    • 9.3.2. UAE Non-Therapeutic Biomolecules Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Trade Pharma
        • 9.3.2.2.2. By End user
    • 9.3.3. South Africa Non-Therapeutic Biomolecules Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Trade Pharma
        • 9.3.3.2.2. By End user

10. South America Non-Therapeutic Biomolecules Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Trade Pharma
    • 10.2.2. By End user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Therapeutic Biomolecules Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Trade Pharma
        • 10.3.1.2.2. By End user
    • 10.3.2. Colombia Non-Therapeutic Biomolecules Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Trade Pharma
        • 10.3.2.2.2. By End user
    • 10.3.3. Argentina Non-Therapeutic Biomolecules Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Trade Pharma
        • 10.3.3.2.2. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Therapeutic Biomolecules Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck Group.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Synthesis Inc.
  • 15.3. Eurogentec
  • 15.4. Aviva Systems Biology
  • 15.5. RayBiotech
  • 15.6. Biocon Limited
  • 15.7. Bio-Techne Corporation
  • 15.8. Danaher Corporation

16. Strategic Recommendations

17. About Us & Disclaimer